San Francisco, California, U.S., September 28, 2026
Nektar Therapeutics is advancing the clinical development of rezpegaldesleukin, its investigational regulatory T-cell-inducing biologic, with three oral presentations scheduled at the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna, Austria. The presentations will feature findings from the company’s Phase 2b REZOLVE-AA and REZOLVE-AD studies evaluating the candidate in alopecia areata and atopic dermatitis, respectively. The program includes new follow-up data examining whether treatment effects persist after therapy is stopped, maintenance findings from atopic dermatitis, and new multi-omic biomarker analyses designed to characterize early molecular responses to treatment.
New Alopecia Areata Data to Assess Durability
One of the three presentations will provide new findings from the Phase 2b REZOLVE-AA study in patients with severe-to-very-severe alopecia areata. The presentation is expected to include six-month, or 24-week, off-treatment data assessing the durability of response using the Severity of Alopecia Tool (SALT) score. The global study enrolled 92 patients who had not previously received a JAK inhibitor or biologic therapy and evaluated two rezpegaldesleukin dose groups against placebo. Patients received twice-monthly subcutaneous injections during the initial treatment period, followed by an optional extension and an off-treatment follow-up period. Earlier Phase 2b findings presented at the 2026 American Academy of Dermatology meeting showed reductions in SALT scores following treatment. In the high-dose group, rezpegaldesleukin produced a 28.2% mean reduction in SALT score at Week 36, compared with 11.2% with placebo; the company also reported statistically significant results after excluding four patients who did not meet major baseline eligibility criteria. The upcoming EADV presentation adds an important dimension by examining what happens after treatment is discontinued.
Rezpegaldesleukin Advances in Atopic Dermatitis
Nektar will also present maintenance data from the Phase 2b REZOLVE-AD study, a global 393-patient trial evaluating rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis. Participants received different dosing regimens during the induction period and eligible responders were subsequently randomized to monthly or quarterly maintenance schedules. The EADV presentation will focus on whether treatment can produce durable and deepening improvements in signs and symptoms with less frequent dosing during the maintenance phase. The company has already moved rezpegaldesleukin into a Phase 3 development program for atopic dermatitis. Nektar initiated the first two registrational ZENITH AD studies in July 2026, with each planned to enroll approximately 510 patients who are biologic- and systemic JAK-inhibitor treatment-naive. A third Phase 3 study is planned for patients with previous systemic biologic or JAK inhibitor treatment. Nektar expects initial Phase 3 topline data in mid-2028.
Multi-Omic Research Explores Immune Response
The third EADV presentation is a late-breaking oral presentation featuring multi-omic profiling from a biomarker substudy of REZOLVE-AD conducted with researchers at the Icahn School of Medicine at Mount Sinai. The research is designed to investigate early molecular responses to rezpegaldesleukin in atopic dermatitis and may provide additional information about how the therapy affects immune pathways associated with the disease. Rezpegaldesleukin is designed to target the interleukin-2 receptor complex and preferentially stimulate the expansion of regulatory T cells (Tregs), which play a central role in maintaining immune tolerance. Nektar is developing the investigational biologic as a potential disease-modifying therapy for several autoimmune and inflammatory diseases, including atopic dermatitis, alopecia areata and type 1 diabetes. The candidate has received FDA Fast Track designation for both atopic dermatitis and severe alopecia areata, although Fast Track designation does not guarantee regulatory approval.
The three EADV presentations provide additional clinical and biological information as Nektar advances rezpegaldesleukin through late-stage development. Importantly, rezpegaldesleukin remains investigational and is not approved for marketing. The upcoming findings will help characterize durability, maintenance dosing and molecular responses as the company progresses its Phase 3 programs.
Source: Nektar Therapeutics press release



